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PPRECLINICAL STUDY
Endothelial Nitric Oxide Synthase
Overexpression Provides a Functionally Relevant
Angiogenic Switch in Hibernating Pig Myocardium
Christian Kupatt, MD,* Rabea Hinkel, DVM,* Marie-Luise von Brühl, DVM,* Tilmann Pohl, MD,*
Jan Horstkotte, MD,* Philip Raake, MD,* Chiraz El Aouni, PHD,* Eckehard Thein, DVM,†
Stefanie Dimmeler, PHD,‡ Olivier Feron, PHD,§ Peter Boekstegers, MD*
Munich and Frankfurt, Germany; Brussels, Belgium
Objectives We investigated whether retroinfusion of liposomal endothelial nitric oxide synthase (eNOS) S1177D complementary
deoxyribonucleic acid (cDNA) would affect neovascularization and function of the ischemic myocardium.
Background Recently, we demonstrated the feasibility of liposomal eNOS cDNA transfection via retroinfusion in a model of
acute myocardial ischemia/reperfusion. In the present study, we used this approach to target a phosphomimetic
eNOS construct (eNOS S1177D) into chronic ischemic myocardium in a pig model of hibernation.
Methods Pigs (n  6/group) were subjected to percutaneous implantation of a reduction stent graft into the left anterior
descending artery (LAD), inducing total occlusion within 28 days. At day 28, retroinfusion of saline solution con-
taining liposomal green fluorescent protein or eNOS S1177D cDNA (1.5 mg/animal, 2  10 min) was per-
formed. Furthermore, L-nitroarginine-methylester (L-NAME) was applied orally from day 28, where indicated. At
day 28 and day 49, fluorescent microspheres were injected into the left atrium for perfusion analysis. Regional
functional reserve (at atrial pacing 140/min) was assessed at day 49 by subendocardial segment shortening
(SES) (sonomicrometry, percent of ramus circumflexus region).
Results The eNOS S1177D overexpression increased endothelial cell proliferation as well as capillary and collateral
growth at day 49. Concomitantly, eNOS S1177D overexpression enhanced regional myocardial perfusion from
62  4% (control) to 77  3% of circumflex coronary artery–perfused myocardium, unless L-NAME was co-
applied (69  5%). Similarly, eNOS S1177D cDNA improved functional reserve of the LAD (33  5% vs. 7  3%
of circumflex coronary artery–perfused myocardium), except for L-NAME coapplication (13  6%).
Conclusions Retroinfusion of eNOS S1177D cDNA induces neovascularization via endothelial cell proliferation and col-
lateral growth. The resulting gain of perfusion enables an improved functional reserve of the hibernating
myocardium. (J Am Coll Cardiol 2007;49:1575–84) © 2007 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.11.047g
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agrowing population of patients who have exhausted
urrent interventional and surgical approaches to treat
oronary malperfusion depend on novel therapeutic ap-
roaches. One strategy potentially meeting the needs of the
no option” patient consists of therapeutic neovasculariza-
ion via growth factors such as the vascular endothelial
rowth factor (VEGF), fibroblast growth factor, insulin-like
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Manuscript received June 7, 2006; revised manuscript received October 19, 2006,
ccepted November 27, 2006.rowth factor (IGF), angiopoietin families among others.
arlier clinical studies using growth factor treatment of the
schemic region yielded mixed results, with singular studies
mproving the record by using advanced regional delivery
1,2) and vector (3) systems. The concept of therapeutic
eovascularization requires angiogenesis (4), defined as
apillary sprouting, as well as arteriogenesis (5,6) (e.g.,
nlargement of preexisting conductance vessels for improve-
ent of tissue perfusion). Recent studies found a contribu-
ion of vasculogenesis (7,8)—using endothelial progenitor
ells—to vessel growth in the adult organism.
Of note, endothelial nitric oxide synthase (eNOS) is a
entral enzyme mediating therapeutic neovascularization. In
ddition to endothelial sprouting, arteriogenesis is impaired
n transgenic mice lacking physiological eNOS activation
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eNOS S1177D Induces Neovascularization in Pigs April 10, 2007:1575–84(9), whereas eNOS overexpres-
sion enhances angiogenesis (10).
Mice lacking eNOS expression
also display impaired vasculo-
genic responses (11). Moreover,
growth factors of the VEGF
(12,13) or IGF family (14) as
well as statins (15), all capable of
increasing perfusion in ischemic
muscle, invariably activate AKT,
which phosphorylates eNOS at a
critical serine residue, S1177
(12,16). This phosphorylation
step is bypassed in a mutant form
of eNOS that carries a phospho-
mimetic amino acid (aspartate)
in place of serine residue 1177
(eNOS S1177D), increasing ni-
tric oxide formation significantly.
Thus, regional transfection of
ischemic muscle tissue with
eNOS S1177D might offer an
attractive option of therapeutic
neovascularization, although this
pproach has not been assessed in larger animals or preclin-
cal settings.
Therefore, we studied the potential of a constitutively
ctive mutant (eNOS S1177D) to improve performance and
erfusion of hibernating myocardium in a preclinical pig
odel. Chronic ischemia of the left anterior descending
rtery (LAD) perfusion area was percutaneously induced by
mplantation of a reduction stent (17). With selective,
ressure-regulated retroinfusion, which proved efficient in
revious studies in pigs (18), we applied liposomes contain-
ng eNOS S1177D regionally to the myocardium 28 days
fter induction of ischemia, a time point at which hibernat-
ng of the myocardium has evolved (17). Evaluation of
yocardial perfusion and function was obtained 3 weeks
ater, to allow for stable neovascularization.
ethods
aterials. All chemicals were purchased from SIGMA
Taufkirchen, Germany). Contrast agent Solutrast 370 was
indly provided by Byk Gulden (Konstanz, Germany). For
ransfection of eNOS S1177D, Effectene (Qiagen, Hilden,
ermany) was used according to the manufacturer’s instruction.
ell adhesion and proliferation in vitro. Rat neonatal
oronary endothelial cells (NCECs) were cultured as previ-
usly described (19). Proliferation of coronary endothelial
ells without or with transfection of eNOS S1177D (with
ffectene) was assessed by Ki67 staining (Novocastra, New-
astle upon Tyne, United Kingdom).
nimal instrumentation. All experimental procedures
ere approved by the Bavarian Animal Care and Use
Abbreviations
and Acronyms
ANOVA  analysis of
variance
cDNA  complementary
deoxyribonucleic acid
cGMP  cyclic guanosine
monophosphate
eGFP  endothelial green
fluorescent protein
eNOS  endothelial nitric
oxide synthase
IGF  insulin-like growth
factor
LAD  left anterior
descending artery
L-NAME  L-nitroarginine-
methylester
RCx  ramus circumflexus
SES  subendocardial
segment shortening
VEGF  vascular
endothelial growth factorommittee. All pig experiments were conducted at the enstitute for Surgical Research of the University of Munich.
erman farm pigs, pretreated with clopidogrel (300 mg)
nd aspirin (300 mg), were anesthetized and instrumented
s previously described (17). The external jugular vein and
he carotid artery of the right side were cannulated and
ppropriate sheaths (8-F) were placed.
schemia. A coronary polytetrafluoroethylene-covered
tent-graft (length 13 mm; Jomed, Germany) was ligated, as
escribed previously (17). Thereafter, the stent was crimped
n a percutaneous transluminal angioplasty-balloon (3.0 
0 mm) and implanted into the proximal LAD. The stent
id not expand at the site of the ligation, resulting in an
our-glass-shaped stenosis of 75% of the luminal diameter.
aintenance of flow in the LAD was monitored invasively
y injection of contrast agent under fluoroscopy at day 7 and
ay 28 (Fig. 1). Of the 40 animals initiated by stent placement,
1 died during the first 28 days (n  7 in between the first
eek), whereas only 1 animal was lost between day 28 and day
9. Five animals were excluded because of early stent occlusion
between day 0 and day 7), inducing myocardial infarction
8% of the left ventricular mass. Of the remaining 24 animals,
8 (n  6/group) were divided into mock transfection en-
anced green fluorescent protein (eGFP), eNOS S1177D, or
NOS S1177D  L-NAME treatment (see the following
ext), whereas 6 animals were transfected with eGFP or eNOS
1177D (n 3 each) at day 7 and killed at day 10 for analysis
f eNOS S1177D transfection (Fig. 2). According to the
nclusion criteria, infarct size (triphenyl-tetrazolium [TTC]-
taining at day 49) was constant across all experimental groups
5.6 2.1% in control subjects, 4.1 1.1% in eNOS S1177D,
nd 4.7  1.8% in eNOS S1177DL-NAME group).
etroinfusion. At day 28, after instrumentation (see pre-
ious), the retroinfusion catheter was advanced into the
nterior interventricular vein (AIV) draining the LAD
erfusion area, as described in detail previously (18). After
ssessment of the individual systolic occlusion pressure of
he venous system, retroinfusion pressure was set 20 mm
g above the latter. Continuous pressure-regulated ret-
oinfusion of isothermic sodium chloride 0.9% (20 ml/
in) with liposomes containing either eGFP complemen-
ary deoxyribonucleic acid (cDNA) (control) or eNOS
1177D was conducted over 2  10 min (1.5 mg cDNA/
nimal). At the same day, 107 fluorescent microspheres were
njected into the left atrium. Reference blood samples were
rawn from the arterial sheath at constant rate (4.1 ml/min).
fter extubation, L-NAME–treated animals received water
ontaining 500 mol/l of the NOS inhibitor for 3 weeks.
emodynamic measurements. At day 28 and day 49,
lobal hemodynamic parameters (heart rate, left ventricular
nd-diastolic pressure [LVEDP], left ventricular pressure
LVP], contraction velocity [dP/dtmax], and relaxation ve-
ocity [dP/dtmin]) were obtained (Table 1). At day 49,
nalysis of regional myocardial function was performed
ssessing subendocardial segment shortening (SES) of isch-
mic versus nonischemic myocardium. Therefore, sonomi-
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April 10, 2007:1575–84 eNOS S1177D Induces Neovascularization in Pigsrometry crystal pairs were placed 1 cm (proximal LAD)
nd 3 cm (distal LAD) distal to the stent into the anterior
V wall. A pair of crystals were inserted in the circumflex
oronary artery (Cx) perfusion area. The distance between
ach crystal pair was followed continuously and evaluated
or 5 heart cycles at each heart rate (at rest, 120 beats/min,
nd 140 beats/min), as previously described (18). Results of
he proximal and distal LAD-perfused area were normal-
zed to the subendocardial segmental shortening of the
ontrol region (Cx perfusion area), given in percent.
lood flow analysis, immunohistochemistry. For assess-
ent of regional myocardial blood flow, fluorescence-
abeled microspheres (molecular probes, 1  107) were
njected into the left atrium at each time point (day 28, day
9). Reference blood samples were drawn from the arterial
heath. Systematic sampling of LV-myocardium (4 to 8
amples of each short axis slice of LV myocardium) allowed
or quantification by an automatized fluorescence detection
Figure 1 Percutaneous Model of Hibernating Myocardium
After percutaneous implantation of a reduction stent in the proximal left anterior d
graphically confirmed at day 10 (top). At day 28, (sub)total occlusion of the LAD w
sion of liposomes with either green fluorescent protein (GFP) or endothelial nitric o
measurements were performed, and tissue was obtained for molecular analysis.rocess (17). Perfusion levels at baseline and after rapid Itrial pacing (140/min, flow reserve) were calculated as
ean of the ischemic and (Cx-perfused) nonischemic area
n the ischemic slices (slice 1  ischemic region near basis,
lice 4  apex). Tissue from nonischemic and ischemic LV
yocardium was used for immunohistochemistry with an-
ibodies against eNOS and inducible NOS (iNOS) (Trans-
uction Lab, Lexington, Kentucky), Ki67 (Novocastra), and
ECAM-1 (Santa Cruz, California). For quantification, 5
elds were counted/region/heart, a microscopic high-power
eld containing 0.0875 mm2. Immunoblotting was per-
ormed with tissue samples that had been frozen in a
ixture of acetone and dry ice, on 12% sodium-
odecylsulfate (SDS)-polyacrylamide gels (Mini-Protean II,
io-Rad, Hercules, California). After transfer to a poly-
inylidene difluoride membrane (Bio-Rad), and blocking,
embranes were incubated with a murine eNOS anti-
ody (Transduction Lab) and subsequently with a goat
nti-mouse immunoglobulin secondary antibody (Jackson
ding artery (LAD) (day 0, arrow) the formation of a high-grade stenosis was angio-
ted with distal filling of the LAD through collaterals. At this time point, retroinfu-
ynthase (eNOS) S1177D was performed. At day 49, hemodynamicescen
as no
xide smmunoResearch Lab, West Grove, Pennsylvania).
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eNOS S1177D Induces Neovascularization in Pigs April 10, 2007:1575–84tatistical methods. The results are given as mean  SEM.
tatistical analysis of results between experimental groups was
erformed with 1-way analysis of variance (ANOVA). Whenever
significant effect was obtained with ANOVA, we performed
ultiple comparison tests between the groups with the Bonferroni
rocedure. All procedures were performed with an SPSS statistical
rogram (version 13.0, SPSS Inc., Chicago, Illinois). Differences
etween groups were considered significant for p  0.05.
esults
NOS overexpression and cell proliferation. In the ische-
Figure 2 eNOS Expression After Retroinfusion of eNOS S1177D
Compared with a control heart (A), endothelial nitric oxide synthase (eNOS) S117
son, inducible NOS (iNOS) was found to be more confined to round cells (arrows),
Immunoblotting of eNOS revealed a 2.3-fold increase of eNOS expression in the is
experiments). (F) Cyclic guanosine monophosphate (cGMP) levels detected by rad
animals, except for L-nitroarginine-methylester (L-NAME) co-application (normalized
LAD  left anterior descending artery; RCx  ramus circumflexus.ic area of transfected hearts, eNOS expression 72 h after hransfection was found higher than in the nonischemic
egion, as depicted in Figure 2. Quantification of cyclic
uanosine monophosphate (cGMP) content of the ischemic
issue (given in % of the nonischemic tissue of the Cx-
erfusion area) revealed an increased formation of cGMP, a
itric oxide sensitive second messenger, in the eNOS
1177D treated hearts (Fig. 2F).
In vitro, eNOS transfection sufficed to induce increased
roliferation of hypoxic coronary endothelial cells (Fig.3),
n effect blunted by L-NAME co-application, indicating
ro-angiogenic endothelial activation. In vivo, a consistently
nsfection enhanced eNOS expression in the ischemic area (B). (C) In compari-
did not express eNOS (D  merged fluorescence). Red bar  50 m. (E)
c region, as compared with the control region (representative example of 3
noassay (RIA) indicate an increased cGMP formation in eNOS S1177D-treated
ischemic tissue, 3 animals/group with 3 tissue specimens/condition each).7D tra
which
chemi
ioimmu
to nonigher number of proliferating cell nuclei was detected in
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April 10, 2007:1575–84 eNOS S1177D Induces Neovascularization in PigsNOS transfected myocardium (Figs. 4A to 4C). Co-
taining with PECAM-1 (Fig. 4D) identified 42  5% of
he proliferating cells displaying Ki67 as endothelial cells,
hereas 21  2% displayed Ki67 and smooth muscle
ntigen. The L-NAME co-application with eNOS blunted
ndothelial cell proliferation (Fig. 4C).
apillary density in hibernating myocardium. In vivo,
mproved perfusion relies on 2 components of the vascula-
ure, microcirculatory vessels (i.e., capillaries and small
rterioles) as well as conductance vessels such as collaterals.
hree days after eNOS-transfection, capillary density of the
schemic area increased, compared with eNOSL-NAME
pplication (Fig. 5B). At day 21, capillary density after
NOS-transfect ion still displayed a trend to capillary
rowth (172  13 capillary/field, p  0.08), whereas after
NOSL-NAME treatment capillary density was un-
hanged to control subjects (control: 145  7; eNOS
117D  L-NAME: 155  8 capillary/field).
ffect of eNOS S1177D on arteriogenesis. Collateral
ormation at day 28 after ischemia induction remained
nchanged between day 28 (2.4 0.4) and day 49 (1.9 0.3)
n the mock-transfected group. However, in the eNOS
1177D-transfected group the number of collaterals was sig-
ificantly increased at day 49 (Fig. 5D). Again, concomitant
-NAME treatment prevented growth of this vessel segment.
ffect of eNOS S1177D transfection on myocardial
lood flow. Because the structural prerequisites of effective
eovascularization, conductance vessel, and microvessel
rowth have been detectable, the level of perfusion of
ibernating myocardium before and after eNOS S1177D
ransfection was analyzed by injection of fluorescent micro-
pheres. At day 28, coronary perfusion of the normoxic
x-perfused myocardium did not differ between groups
Figs. 6A and 6B). At day 49, LAD perfusion of control
nimals was reduced at rest (62 4% of Cx perfusion) (Fig.
E) as well as at rapid atrial pacing (65  3%) (Fig. 6F),
hile Cx-perfusion itself increased by 36% under pacing
emodynamic Assessment of Pig Hearts
Table 1 Hemodynamic Assessment of Pig Hearts
Experimental Group Control Group eNOS S1177D
eNOS S1177D 
L-NAME
Heart rate (min1)
D28 88 6 77 4 84 7
D56 85 4 81 5 85 6
LVEDP (mm Hg)
D28 18.7 1.2 19.5 0.6 18.4 1.1
D56 20.5 1.1 17.1 0.8 20.6 1.8
LVSP (mm Hg)
D28 103 4 100 4 102 3
D56 94 4 96 4 106 5
dP/dtmax (mm Hg/s) 1,358 111 1,334 75 1,385 24
dP/dtmin (mm Hg/s) 1,195 175 1,122 46 1,316 122
P/dtmax  contraction velocity; dP/dtmin  relaxation velocity; eNOS  endothelial nitric oxide
ynthase; L-NAME  L-nitroarginine-methylester; LVEDP  left ventricular enddiastolic pressure;
VSP  left ventricular systolic pressure.data not shown). After eNOS S1177D-transfection, per-usion of ischemic area increased to 77  3% (at rest) and
0  5% (140/min) (Figs. 6C to 6F, Table 2). Addition of
-NAME prevented a significant increase of LAD-
erfusion above control levels (69  3% and 70  5% of
x-perfusion, respectively) (Figs. 6E and 6F).
egional myocardial function at rest and atrial pacing.
iven the chronic ischemic hibernating myocardium
nduced by a reduction stent, as used in the present study,
hanges in perfusion of the ischemic region were poten-
ially capable of translating into changes of myocardial
erformance. We assessed regional myocardial function
ia sonomicrometry of the ischemic versus the normally
erfused control area. Subendocardial segment shorten-
ng of the proximal ischemic LAD area amounted to
3  12% of the Cx-perfused area and did not signifi-
antly change during atrial pacing or when compared
ith eNOS S1177D transfection with or without
-NAME. In constrast, in the distal LAD area, at higher
eart rates an improved preservation of SES was found in
NOS S1177D-transfected animals (41  8% and 33 
% at 120/min and 140/min, respectively), whereas
ock-transfected animals displayed a significant loss of
yocardial function at 140/min (7  4%) (Fig. 7).
egional contraction of the ischemic area after eNOS 
-NAME treatment did not differ from the level of
ock-transfected animals.
iscussion
n the present study, we demonstrated that retroinfusion of
NOS S1177D cDNA (Fig. 2) into a region of hibernating
yocardium was efficiently inducing neovascularization
Figs. 5 and 6) and improvement of myocardial function
Fig. 7) in a preclinical pig model. In vitro and in vivo
nalysis indicated a role of endothelial proliferation in the
eovascularization response to eNOS S1177D overexpres-
ion (Figs. 3 and 4).
Figure 3 Endothelial Cells Proliferate
After eNOS S1177D Transfection In Vitro
Proliferation of hypoxic coronary endothelial cells (CECs) is increased after endo-
thelial nitric oxide synthase (eNOS) S1177D transfection (n  4 independent
experiments). H/R  hypoxia-reoxygenation; L-NAME  L-nitroarginine-methylester.
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eNOS S1177D Induces Neovascularization in Pigs April 10, 2007:1575–84odel of hibernation. For induction of critical ischemia in
he myocardium, we chose percutaneous reduction stent
mplantation, resulting in an acute 75% stenosis that pro-
ressed to total occlusion at day 28 (Fig. 1). Percutaneous
mplantation allowed for atraumatic induction of hiberna-
ion over 4 weeks, which was confirmed by 18 fluorodeoxy-
lucose (FDG)- and 13 ammonium (NH3)-positron emis-
ion tomography (17). Thereafter, myocardial perfusion of
he ischemic region is unaltered in mock-transfected control
ubjects (Figs. 6C and 6D). Capillary densities at day 28 and
Figure 4 Endothelial Cells Proliferate After eNOS S1177D Tran
Histochemical evaluation proliferation (Ki67 positivity) in control (A) and ischemic
ation in eNOS S1177D transfected tissue (3 experiments/group with 5 tissue spe
of Ki67 (left), endothelial marker platelet endothelial adhesion molecule-1 (PECAMay 49 indicate that rarification of microvessels is accompa- pying the development of hibernation (Fig. 5A), a phenom-
non confirmed in patient biopsies (20). By virtue of the
tudy protocol, treatment initiated at day 28 is exclusively
argeting chronic ischemia, avoiding interference with the
hysiologic response to acute ischemia, which is also af-
ected by eNOS (18). The gradual induction of ischemia by
ercutaneous reduction stent implantation is similar to
meroid constrictor ring placement, which requires, how-
ver, lateral thoracotomy with a larger wound area (21).
his feature also accompanies another surgical approach,
ion In Vivo
sue. Red bar  50 m. (C) Quantitative analysis revealed an increased prolifer-
s/condition each). Cx  circumflex coronary artery. (D) Fluorescence microscopy
iddle), and overlay (right), red bar  10 m. Abbreviations as in Figure 2.sfect
(B) tis
cimen
-1) (mlacement of a Delran occluder with a fixed internal
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April 10, 2007:1575–84 eNOS S1177D Induces Neovascularization in Pigsiameter around the target coronary vessel (22). In accor-
ance with the latter model, basal flow in the ischemic
yocardium of our experiments was decreased as compared
ith the nonischemic myocardium (Fig. 6), confirming
ibernating myocardium.
NOS expression. For eNOS S1177D transfection, retro-
nfusion of the liposome-cDNA mix was applied, as de-
cribed in detail before (18). This application method
articularly suits the context of chronic ischemia due to
evere arterial stenosis, because the unaffected venous vas-
ulature can be used for prolonged transfection applying
ow reversal and concomitant venous outflow blockade.
ith that approach, a 2.3-fold overexpression of the eNOS
onstruct is achieved in the ischemic region, in accordance
ith previous studies using this approach to transfect an
schemic myocardial region (18,23,24). This expression level
ufficed to enhance the levels of cGMP—a second messen-
er formed upon nitric oxide exposure—in the ischemic
issue, unless the NOS inhibitor L-NAME was co-applied.
lthough L-NAME potentially exerts a detrimental effect
y unselectively inhibiting NOS activity of native and forced
OS expression, we have not observed L-NAME–induced
Figure 5 Capillary and Collateral Growth After eNOS S1177D T
(A) Example of platelet endothelial adhesion molecule-1 staining of capillaries (red
nitric oxide synthase (eNOS) S1177D-transfected animals displayed increased cap
The pro-angiogenic effect was found attenuated at day 49. (D) However, the numb
transfection (n  6/group).oss of function in pig hearts (18) at the dosage used in this ctudy. Moreover, L-NAME uptake was stopped 24 h before
he day 49 measurements in order to rule out an acute effect
f NOS-inhibition.
NOS and neovascularization. Although endothelial
OS is centrally involved in rapid regulation of vascular
one and vessel adhesivity, a role in vascular homeostasis has
een suggested before (15,25–27). With respect to the
lements of neovascularization, angiogenesis (25), arterio-
enesis (28), and vasculogenesis (11), eNOS seems to play a
ignificant role, in particular in VEGF-mediated vascular
esponses (12,26). Concerning vasculogenesis, regional
verexpression of eNOS through a constitutively active
utant was unable to alter bone marrow mobilization (29).
owever, proliferation of endothelial cells was induced in
itro and in vivo (Figs. 3A and 4), increasing capillary
ensity in the hibernating myocardial region (Fig. 5A). A
imilar observation has been obtained from studies in
schemic hindlimb models, where transfection (30) or acti-
ation of eNOS (31) resulted in increased capillary/muscle
ber ratios. Moreover, arteriogenesis, providing conduc-
ance vessels required for perfusion of distant tissue, was
nhanced by eNOS transfection (Fig. 5D). Of note, mono-
ection In Vivo
100 m). (B) Three days after transfection, the ischemic area of endothelial
evels compared with the eNOS L-nitroarginine-methylester (L-NAME) group. (C)
ollaterals at day 49 (postmortem angiogram) was increased after eNOS S1177Dransf
bar 
illary l
er of cyte recruitment, a hallmark of arteriogenesis, is not directly
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eNOS S1177D Induces Neovascularization in Pigs April 10, 2007:1575–84pregulated by eNOS overexpression in vitro (data not
hown). In contrast, monocyte chemoattractant protein
MCP)-1 application (32), which initiates arteriogenesis by
nhancing monocyte recruitment, might induce vascular
nflammation similar to an arteriosclerotic phenotype (33)
nd is associated with an unfavorable outcome in patients
resenting with an acute coronary syndrome (34). This
bservation does not rule out a role of, for example, resident
acrophages for arteriogenesis (35) after eNOS S1177D
reatment but limits their triggering role for initiation of
eovascularization induced by nitric oxide. In our study, a
irect effect of nitric oxide formed in eNOS S1177D–
ransfected veins or increased shear stress due to a growing
Figure 6 Forced eNOS S1177D Expression Improves Perfusion
At day 28 (A) and day 49 (B), regional myocardial perfusion in the RCx region at r
short-axis tissue slice, slice 4  apex). (C) The LAD perfusion at day 28 was redu
area was significantly improved in the eNOS S1177D-treated hearts, as compared
atrial pacing, the LAD perfusion/RCx perfusion ratio was significantly improved in t
jects, eNOS S1177D, n  5 for eNOS S1177D  L-NAME). Cx  circumflex coronapillary bed (Fig. 5B)—which have also been observed in a ahronic rabbit hindlimb ischemia model (31,36)—have
ost likely contributed to arteriogenesis after eNOS trans-
ection. A similar combination of microvascular and macro-
ascular growth was achieved by chronic L-arginine supple-
entation in hypercholesterinemic pigs 7 weeks after
meroid ring placement (37).
ifferential regulation of endothelial versus smooth muscle
roliferation. In our experiments, immunohistology indicated
hat 1 hallmark of neovasculatory response of eNOS was cell
roliferation. Co-staining identified the majority of prolif-
rating cells displaying Ki67 positivity as endothelial cells,
hich are known to respond to eNOS activation by prolif-
ration and migration (10,38). In contrast, L-NAME co-
hemic Myocardium
s similar in all groups at resting heart rate (slice 1  most proximal ischemic
the same extent in all groups. (D) Myocardial perfusion of the apical ischemic
ontrol or L-NAME co-treated animals. (E) At resting heart rate and (F) at rapid
OS S1177D hearts, when compared with control hearts (n  6 for control sub-
ery; other abbreviations as in Figure 2.of Isc
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ositive enhanced smooth muscle cell proliferation causing
egative remodeling of a carotid artery after injury (28),
hereas forced eNOS expression abolishes smooth muscle
roliferation (39). These findings support the notion that
NOS activity controls neovascularization by reciprocally
ctivating endothelial proliferation and inhibiting smooth
uscle cell proliferation and luminal loss (28,29).
linical perspective. In summary, we report a neovascu-
atory response of chronic ischemic myocardium after re-
ional transfection of a constitutively active eNOS construct
eNOS S1177D), which relied on capillary proliferation as
ell as collateral growth and was sensitive to NO-inhibition
ia L-NAME. Enhanced perfusion and an improved re-
ponse to stress testing (rapid atrial pacing) indicate that this
pproach provided functionally relevant neovascularization.
lthough the sensitivity of experimental detection of per-
usion and function of the ischemic myocardium might not
e directly translated to the clinical setting, recent advances
n magnetic resonance imaging for clinical assessment of
Figure 7 Regional Gain of Myocardial Function in the Distal LA
Regional myocardial function was assessed by subendocardial segment shortenin
proximal (A) or distal LAD region (B) at rest or after atrial pacing (120/min and 1
Regional Myocardial Blood Flow in Epicardial an
Table 2 Regional Myocardial Blood Flow in
Experimental Group
Perfusion
(ml/min/g tissue)
Control Group
Epicardial Endocardial
D28
LAD 1.08 0.15 1.08 0.08 0
RCx 1.60 0.04 1.62 0.15 1
D56 rest
LAD 0.85 0.06 0.73 0.05 1
RCx 1.38 0.05 1.23 0.06 1
D56 pacing
LAD 1.19 0.07 1.08 0.06 1
RCx 1.77 0.09 1.72 0.04 1
*p  0.05 versus corresponding tissue of the control group.
LAD  left anterior descending artery; RCx  ramus circumflexus; ooronary perfusion (40,41) and function (42) seem particu-
arly promising for detection of perfusion changes induced
y neovascularization. Moderately enhancing NO bioavail-
bility via eNOS cDNA retroinfusion might offer a thera-
eutic approach in patients with hibernating myocardium
ot accessible to conventional revascularization.
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Methods) at day 49 in the
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docardial Tissue Samples
rdial and Endocardial Tissue Samples
eNOS S1177D eNOS S1177D  L-NAME
rdial Endocardial Epicardial Endocardial
0.07 1.01 0.07 0.97 0.11 0.99 0.10
0.12 1.57 0.06 1.49 0.14 1.55 0.04
0.06* 1.06 0.06* 0.94 0.07 0.82 0.06
0.07 1.45 0.05 1.37 0.09 1.29 0.06
0.12* 1.41 0.09* 1.45 0.06 1.34 0.09
0.08 1.80 0.07 2.02 0.15 1.93 0.11
breviations as in Table 1.D Re
g (see
40/mid En
Epica
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